Skip to content

Group News

Aspen’s offshore operations drive an impressive 91% revenue increase

Mar 5, 2009

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong revenue growth for the six months ended 31 December 2008. The positive returns were stimulated by Aspen’s recently expanded international operations. The existing businesses in South Africa and Australia have once again recorded sustained growth. Revenue increased by 91 percent to R4…

Read More >>

Trading Update

Feb 12, 2009

Aspen shareholders are hereby advised that earnings per share, for the 6 months ended 31 December 2008, are forecast to exceed those reported in the comparative period ended 31 December 2007, by 45-60%. Headline earnings per share are forecast to exceed those of the comparative period by 65-80%. As anticipated, a strong contribution from Aspen’s…

Read More >>

Aspen Appoints Noel Guliwe as Chief Executive in South Africa

Jan 12, 2009

JOHANNESBURG: Aspen Holdings is pleased to announce the appointment by its principal South African subsidiary of Noel Guliwe as Chief Executive: South Africa with effect from January 12, 2009. “The rapid globalization of the Aspen Group has necessitated increased attention from Aspen’s senior executives. Consequently, this appointment has been made to ensure that the local…

Read More >>

Aspen Matrix Release

Oct 9, 2008

Aspen Pharmacare Holdings Limited (“Aspen”) and Matrix Laboratories Limited (“Matrix”) of the Republic of India, would like to announce the divestment of the existing joint ventures relating to the two chemical-manufacturing entities, Fine Chemicals Corporation (Proprietary) Limited (“FCC”) in Cape Town, South Africa and Astrix Laboratories (“Astrix”) Limited in Hyderabad, India. Aspen will acquire 50%…

Read More >>

Aspen establishes its international platform for future growth

Sep 16, 2008

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, is pleased to announce positive results for the year ended 30 June 2008. The Group delivered sustained growth from its existing bases in South Africa, Australia and Asia. A series of significant transactions were concluded to expand the Group’s footprint into Latin America,…

Read More >>

Revision of Terms of Aspen`s Investment in Strides` Latin American Operations

Sep 16, 2008

Further to the announcement made on 20 November 2007, Aspen is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“Global”) has agreed revised terms with Strides Arcolab Limited (“Strides”), a pharmaceutical company registered in the Republic of India, in respect of certain aspects of Global’s acquisition of an interest in Strides’ Latin…

Read More >>

Aspen Businesses in Licensing Deal With GSK

Jul 22, 2008

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced today that it has entered into licensing and supply agreements with leading multinational pharmaceutical corporation, GlaxoSmithKline (“GSK”). In terms of the agreements Aspen will license intellectual property and supply finished dosage form pharmaceuticals to GSK through Aspen Group companies including Onco Therapies Limited (“OTL”),…

Read More >>

Aspen Invests R2.7 Billion in Expanding Global Business

Jun 30, 2008

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced an investment by its offshore subsidiary, Aspen Global Incorporated, of GBP 170 million (approximately R2.7 billion) for the acquisition of four pharmaceutical products from GlaxoSmithKline (GSK). Aspen Global has acquired the intellectual property rights to the branded pharmaceuticals Eltroxin, Imuran, Lanoxin and Zyloric for…

Read More >>

Aspen wins significant portion of ARV tender

Jun 25, 2008

In addition to maintaining the supply contract for existing tender items, Aspen has also secured volumes for two new products, Aspen Efavirenz and Tenofivir. Tenofivir is a key new molecule to the ARV tender. Increased usage is anticipated over the tender period. Aspen secured more than 50% by volume of the entire ARV tender based…

Read More >>

Shelys Africa Limited

May 5, 2008

Aspen Pharmacare Holdings Limited is pleased to announce the conclusion of a deal for the acquisition of 60% of the share capital of Shelys Africa Limited, with operations in East and Central Africa with effect from 01 May 2008. Shelys Africa Limited is the holding company of a group of East African pharmaceutical companies (“the…

Read More >>

CONTACT DETAILS

Shauneen Beukes
Group Communications Manager
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Scroll To Top